These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

70 related articles for article (PubMed ID: 2818679)

  • 41. High-dose idarubicin in combination with Ara-C in patients with relapsed or refractory acute lymphoblastic leukemia: a pharmacokinetic and clinical study.
    Tedeschi A; Montillo M; Strocchi E; Cafro AM; Tresoldi E; Intropido L; Nichelatti M; Marbello L; Baratè C; Camaggi CM; Morra E
    Cancer Chemother Pharmacol; 2007 May; 59(6):771-9. PubMed ID: 17256136
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Vincamine concentrations in plasma and cerebrospinal fluid in patients following intravenous infusion (author's transl)].
    Siegers CP; Heiss WD; Kohlmeyer K
    Arzneimittelforschung; 1977; 27(6a):1274-7. PubMed ID: 578452
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Pharmacokinetics of mexiletine in renal insufficiency.
    Baudinet G; Henrard L; Quinaux N; El Allaf D; de Landsheere C; Carlier J; Dresse A
    Acta Cardiol Suppl; 1980; (25):55-65. PubMed ID: 6966453
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A schedule for combined intravenous and oral dosing with mexiletine.
    Holt DW; Hampel G; Volans GN
    J Int Med Res; 1979; 7(2):162-4. PubMed ID: 478163
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Pharmacokinetics of oral mexiletine in patients with acute myocardial infarction.
    Pentikäinen PJ; Halinen MO; Helin MJ
    Eur J Clin Pharmacol; 1983; 25(6):773-7. PubMed ID: 6662176
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Effect of oral combination therapy with mexiletine and quinidine on left and right ventricular function.
    Sheldon RS; Duff HJ; Mitchell LB; Wyse DG; Manyari DE
    Am Heart J; 1988 May; 115(5):1030-6. PubMed ID: 3284310
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Mexiletine, an anti-arrhythmia agent for acute stage of myocardial infarction].
    Hayakawa H; Ino T
    Nihon Rinsho; 1983 Dec; 41(12):2748-55. PubMed ID: 6674559
    [No Abstract]   [Full Text] [Related]  

  • 48. Plasma concentrations and acceptability of mexiletine given by intramuscular injection in patients admitted to a coronary care unit.
    Nicholas J; Boyle DM; Kinney CD; Salathia K; Shanks RG
    J Cardiovasc Pharmacol; 1986; 8(1):21-8. PubMed ID: 2419687
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Influence of experimental diabetes and insulin treatment on the enantioselective pharmacokinetics of mexiletine and its metabolites.
    Pardo Campos Godoy AL; Martinez EZ; Marques MP; de Carvalho Leone A; Barbosa Coelho E; Lucia Lanchote V
    Can J Physiol Pharmacol; 2014 Mar; 92(3):263-6. PubMed ID: 24593792
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Simultaneous modelling of mexiletine and hydroxy-methyl-mexiletine data after single- and multiple-dose administration of a sustained-release mexiletine formulation.
    Bruno R; Santoni Y; Iliadis A; Djiane P; Serradimigni A; Cano JP
    Biopharm Drug Dispos; 1992 Oct; 13(7):481-93. PubMed ID: 1489940
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The effects of intravenous mexiletine on spectra of the signal-averaged ECG.
    Zaliunas R; Zabiela P; Slapikas R; Vainoras A; Pentiokiniene D; Levisauskiene R; Bechtold H; Meyer U
    Pacing Clin Electrophysiol; 1994 Nov; 17(11 Pt 2):2187-93. PubMed ID: 7845841
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Clinical pharmacokinetics of intravenous flecainide in critically ill patients.
    Sangrador G; Sánchez-Alcaraz A; Rodriguez M; Ibáñez P
    J Clin Pharm Ther; 1989 Aug; 14(4):309-14. PubMed ID: 2507556
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Kinetics and bioavailability of mexiletine in healthy subjects.
    Häselbarth V; Doevendans JE; Wolf M
    Clin Pharmacol Ther; 1981 Jun; 29(6):729-36. PubMed ID: 7226704
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Mexiletine metabolites: a review.
    Catalano A; Carocci A; Sinicropi MS
    Curr Med Chem; 2015; 22(11):1400-13. PubMed ID: 25723511
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Lidocaine pharmacokinetics and substantiation of the new method of its administration in myocardial infarct].
    Piotrovskiĭ VK; Smirnova EB; Riabokon' OS; Mazur NA; Metelitsa VI
    Kardiologiia; 1979 Jul; 19(7):23-7. PubMed ID: 470315
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Some health problems among the Chontals of Tabasco, Mex.
    RUSSELL JE
    Am Indig; 1947 Oct; 7(4):315-21. PubMed ID: 20272352
    [No Abstract]   [Full Text] [Related]  

  • 57. Clinical pharmacokinetics of mexiletine.
    Labbé L; Turgeon J
    Clin Pharmacokinet; 1999 Nov; 37(5):361-84. PubMed ID: 10589372
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Mexiletine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in the treatment of arrhythmias.
    Monk JP; Brogden RN
    Drugs; 1990 Sep; 40(3):374-411. PubMed ID: 2226221
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Mexiletine in acute myocardial infarction. Simulation of a theoretical protocol and validation in six patients.
    Lévy-Prades R; Philip F; Danays T; Serradimigni A; Cano JP
    Arzneimittelforschung; 1989 Aug; 39(8):903-8. PubMed ID: 2818679
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Pharmacokinetics of intravenous mexiletine in patients with acute myocardial infarction.
    Pentikäinen PJ; Halinen MO; Helin MJ
    J Cardiovasc Pharmacol; 1984; 6(1):1-6. PubMed ID: 6199590
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.